Estimated per patient costs (£000s) related specifically to HCV related complications (excluding any HCV therapy costs) stratified by age, discounting, fibrosis stage and SVR.

Financial impact of treatment coverage for the entire estimated population of people with HCV who require treatment with sofosbuvir or ledipasvir/sofosbuvir.

Swathi Iyengar (3166167)
Kiu Tay-Teo (3166161)
Sabine Vogler (3131850)
Peter Beyer (21528)
Stefan Wiktor (3166158)
Kees de Joncheere (3166164)
Suzanne Hill (160643)

May 2016

Fig 3 shows the financial impact of covering the entire estimated population of people with HCV w...

Sensitivity analyses of cost-effectiveness results by age at time of treatment, cost of anti-HCV drug therapy and annual discount rate.

Rakesh Aggarwal (840885)
Qiushi Chen (765659)
Amit Goel (4030883)
Nicole Seguy (4030874)
Razia Pendse (4030880)
Turgay Ayer (4030877)
Jagpreet Chhatwal (299895)

May 2017

Sensitivity analyses of cost-effectiveness results by age at time of treatment, cost of anti-HCV ...

Estimation of average diagnosis and treatment costs of hepatitis C

Hepatology From
Bed Bench
Sara Ashtari
Mohsen Vahedi
Mohamad Amin Pourhoseingholi
Asma Pourhoseingholi
Azadeh Safaee
Mohammad Reza Zali

August 2016

Aim: the objective of this study was to estimate the average cost of diagnosis and treatment of hepa...

Cost per SVR associated with SVR rates corresponding to the five steps in the development of HCV therapies over time (SVR steadily increases with time).

Nathalie Vernaz (289981)
François Girardin (418191)
Nicolas Goossens (2838929)
Urs Brügger (2838935)
Marco Riguzzi (2838932)
Arnaud Perrier (79909)
Francesco Negro (205592)

June 2016

Cost per SVR associated with SVR rates corresponding to the five steps in the development of HCV ...

Mean SVR, mean costs, costs per SVR and confidence intervals (CI) of HCV treatments over time in Switzerland and the US (Tables F-J in S1 File).

Nathalie Vernaz (289981)
François Girardin (418191)
Nicolas Goossens (2838929)
Urs Brügger (2838935)
Marco Riguzzi (2838932)
Arnaud Perrier (79909)
Francesco Negro (205592)

June 2016

Mean SVR, mean costs, costs per SVR and confidence intervals (CI) of HCV treatments over time in ...

The cost of treatment coverage with sofosbuvir or ledipasvir/sofosbuvir of different proportions of patients with viraemic HCV infection (for point estimates and uncertainty intervals) as a proportion of PPP-adjusted current total pharmaceutical expenditure.

Swathi Iyengar (3166167)
Kiu Tay-Teo (3166161)
Sabine Vogler (3131850)
Peter Beyer (21528)
Stefan Wiktor (3166158)
Kees de Joncheere (3166164)
Suzanne Hill (160643)

May 2016

The cost of treatment coverage with sofosbuvir or ledipasvir/sofosbuvir of different proportions ...

Costs associated with the five steps in HCV therapy development over time (SVR steadily increases with time).

Nathalie Vernaz (289981)
François Girardin (418191)
Nicolas Goossens (2838929)
Urs Brügger (2838935)
Marco Riguzzi (2838932)
Arnaud Perrier (79909)
Francesco Negro (205592)

June 2016

Costs associated with the five steps in HCV therapy development over time (SVR steadily increases...

Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

Sara Ashtari
Mohsen Vahedi
Maryam Karkhane
Zahra Kimiia
Asma Pourhoseingholi
Azadeh Safaee
Bijan Moghimi-dehkordi
Seyed Moayed Alavian

August 2016

Background: HCV virus (HCV) is a significant global problem with wide-ranging socio-economic impacts...

Total costs of the primary care HCV treatment program, related to staffing and wholesale acquisition cost of HCV medications, 2015–2016.

Eric A. Jones (568877)
Benjamin P. Linas (565873)
Ve Truong (6458843)
James F. Burgess (6458846)
Karen E. Lasser (4824885)

March 2019

Total costs of the primary care HCV treatment program, related to staffing and wholesale acquisition...

Using statistical models to assess medical cost of hepatitis C virus

Mohsen Vahedi
Asma Pourhoseingholi
Sara Ashtari
Mohamad Amin Pourhoseingholi
Maryam Karkhane
Bijan Moghimi-dehkordi
Azadeh Safaee
Zahra Kimia
Seyed Moayed Alavian

August 2016

Aim: This study compared PR and NB in predicting HCV patient costs. The objective of this study was ...

Estimated per-patient QALYs stratified by age, discounting, current fibrosis stage and SVR.

Phil McEwan (688067)
Thomas Ward (688068)
Hayley Bennett (688069)
Anupama Kalsekar (688070)
Samantha Webster (688071)
Michael Brenner (688072)
Yong Yuan (253559)

January 2015

Estimated per-patient QALYs stratified by age, discounting, current fibrosis stage and SVR.</p

Estimated cost per patient per year (excluding the cost of antiviral therapy), by disease stage, in 2011 Euros.

Beat Müllhaupt (416436)
Philip Bruggmann (760024)
Florian Bihl (760025)
Sarah Blach (760026)
Daniel Lavanchy (739213)
Homie Razavi (760027)
David Semela (416437)
Francesco Negro (205592)

June 2015

(* Base costs were calculated as described above, ** Low costs represent the minimum cost associa...

PPP-adjusted financial impact of treatment coverage for all patients with viraemic HCV infection (for point estimates and uncertainty intervals) with sofosbuvir or ledipasvir/sofosbuvir.

Swathi Iyengar (3166167)
Kiu Tay-Teo (3166161)
Sabine Vogler (3131850)
Peter Beyer (21528)
Stefan Wiktor (3166158)
Kees de Joncheere (3166164)
Suzanne Hill (160643)

May 2016

PPP-adjusted financial impact of treatment coverage for all patients with viraemic HCV infection ...

Hepatology

ConclusionImmediate treatment of HCV-infected patients with moderate and advanced fibrosis appears t...

Total Costs and revenue of primary care HCV treatment program, according to presence or absence of the 340b drug pricing program.

Eric A. Jones (568877)
Benjamin P. Linas (565873)
Ve Truong (6458843)
James F. Burgess (6458846)
Karen E. Lasser (4824885)

March 2019

Total Costs and revenue of primary care HCV treatment program, according to presence or absence of t...

Financial impact of treatment coverage for the entire estimated population of people with HCV who require treatment with sofosbuvir or ledipasvir/sofosbuvir.

Swathi Iyengar (3166167)
Kiu Tay-Teo (3166161)
Sabine Vogler (3131850)
Peter Beyer (21528)
Stefan Wiktor (3166158)
Kees de Joncheere (3166164)
Suzanne Hill (160643)

May 2016

Fig 3 shows the financial impact of covering the entire estimated population of people with HCV w...

Sensitivity analyses of cost-effectiveness results by age at time of treatment, cost of anti-HCV drug therapy and annual discount rate.

Rakesh Aggarwal (840885)
Qiushi Chen (765659)
Amit Goel (4030883)
Nicole Seguy (4030874)
Razia Pendse (4030880)
Turgay Ayer (4030877)
Jagpreet Chhatwal (299895)

May 2017

Sensitivity analyses of cost-effectiveness results by age at time of treatment, cost of anti-HCV ...

Estimation of average diagnosis and treatment costs of hepatitis C

Hepatology From
Bed Bench
Sara Ashtari
Mohsen Vahedi
Mohamad Amin Pourhoseingholi
Asma Pourhoseingholi
Azadeh Safaee
Mohammad Reza Zali

August 2016

Aim: the objective of this study was to estimate the average cost of diagnosis and treatment of hepa...

Cost per SVR associated with SVR rates corresponding to the five steps in the development of HCV therapies over time (SVR steadily increases with time).

Nathalie Vernaz (289981)
François Girardin (418191)
Nicolas Goossens (2838929)
Urs Brügger (2838935)
Marco Riguzzi (2838932)
Arnaud Perrier (79909)
Francesco Negro (205592)

June 2016

Cost per SVR associated with SVR rates corresponding to the five steps in the development of HCV ...

Mean SVR, mean costs, costs per SVR and confidence intervals (CI) of HCV treatments over time in Switzerland and the US (Tables F-J in S1 File).

Nathalie Vernaz (289981)
François Girardin (418191)
Nicolas Goossens (2838929)
Urs Brügger (2838935)
Marco Riguzzi (2838932)
Arnaud Perrier (79909)
Francesco Negro (205592)

June 2016

Mean SVR, mean costs, costs per SVR and confidence intervals (CI) of HCV treatments over time in ...

The cost of treatment coverage with sofosbuvir or ledipasvir/sofosbuvir of different proportions of patients with viraemic HCV infection (for point estimates and uncertainty intervals) as a proportion of PPP-adjusted current total pharmaceutical expenditure.

Swathi Iyengar (3166167)
Kiu Tay-Teo (3166161)
Sabine Vogler (3131850)
Peter Beyer (21528)
Stefan Wiktor (3166158)
Kees de Joncheere (3166164)
Suzanne Hill (160643)

May 2016

The cost of treatment coverage with sofosbuvir or ledipasvir/sofosbuvir of different proportions ...

Costs associated with the five steps in HCV therapy development over time (SVR steadily increases with time).

Nathalie Vernaz (289981)
François Girardin (418191)
Nicolas Goossens (2838929)
Urs Brügger (2838935)
Marco Riguzzi (2838932)
Arnaud Perrier (79909)
Francesco Negro (205592)

June 2016

Costs associated with the five steps in HCV therapy development over time (SVR steadily increases...

Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

Sara Ashtari
Mohsen Vahedi
Maryam Karkhane
Zahra Kimiia
Asma Pourhoseingholi
Azadeh Safaee
Bijan Moghimi-dehkordi
Seyed Moayed Alavian

August 2016

Background: HCV virus (HCV) is a significant global problem with wide-ranging socio-economic impacts...

Total costs of the primary care HCV treatment program, related to staffing and wholesale acquisition cost of HCV medications, 2015–2016.

Eric A. Jones (568877)
Benjamin P. Linas (565873)
Ve Truong (6458843)
James F. Burgess (6458846)
Karen E. Lasser (4824885)

March 2019

Total costs of the primary care HCV treatment program, related to staffing and wholesale acquisition...

Using statistical models to assess medical cost of hepatitis C virus

Mohsen Vahedi
Asma Pourhoseingholi
Sara Ashtari
Mohamad Amin Pourhoseingholi
Maryam Karkhane
Bijan Moghimi-dehkordi
Azadeh Safaee
Zahra Kimia
Seyed Moayed Alavian

August 2016

Aim: This study compared PR and NB in predicting HCV patient costs. The objective of this study was ...

Estimated per-patient QALYs stratified by age, discounting, current fibrosis stage and SVR.

Phil McEwan (688067)
Thomas Ward (688068)
Hayley Bennett (688069)
Anupama Kalsekar (688070)
Samantha Webster (688071)
Michael Brenner (688072)
Yong Yuan (253559)

January 2015

Estimated per-patient QALYs stratified by age, discounting, current fibrosis stage and SVR.</p

Estimated cost per patient per year (excluding the cost of antiviral therapy), by disease stage, in 2011 Euros.

Beat Müllhaupt (416436)
Philip Bruggmann (760024)
Florian Bihl (760025)
Sarah Blach (760026)
Daniel Lavanchy (739213)
Homie Razavi (760027)
David Semela (416437)
Francesco Negro (205592)

June 2015

(* Base costs were calculated as described above, ** Low costs represent the minimum cost associa...

PPP-adjusted financial impact of treatment coverage for all patients with viraemic HCV infection (for point estimates and uncertainty intervals) with sofosbuvir or ledipasvir/sofosbuvir.

Swathi Iyengar (3166167)
Kiu Tay-Teo (3166161)
Sabine Vogler (3131850)
Peter Beyer (21528)
Stefan Wiktor (3166158)
Kees de Joncheere (3166164)
Suzanne Hill (160643)

May 2016

PPP-adjusted financial impact of treatment coverage for all patients with viraemic HCV infection ...

Hepatology

ConclusionImmediate treatment of HCV-infected patients with moderate and advanced fibrosis appears t...

Total Costs and revenue of primary care HCV treatment program, according to presence or absence of the 340b drug pricing program.

Eric A. Jones (568877)
Benjamin P. Linas (565873)
Ve Truong (6458843)
James F. Burgess (6458846)
Karen E. Lasser (4824885)

March 2019

Total Costs and revenue of primary care HCV treatment program, according to presence or absence of t...

Financial impact of treatment coverage for the entire estimated population of people with HCV who require treatment with sofosbuvir or ledipasvir/sofosbuvir.

Swathi Iyengar (3166167)
Kiu Tay-Teo (3166161)
Sabine Vogler (3131850)
Peter Beyer (21528)
Stefan Wiktor (3166158)
Kees de Joncheere (3166164)
Suzanne Hill (160643)

May 2016

Fig 3 shows the financial impact of covering the entire estimated population of people with HCV w...

Sensitivity analyses of cost-effectiveness results by age at time of treatment, cost of anti-HCV drug therapy and annual discount rate.

Rakesh Aggarwal (840885)
Qiushi Chen (765659)
Amit Goel (4030883)
Nicole Seguy (4030874)
Razia Pendse (4030880)
Turgay Ayer (4030877)
Jagpreet Chhatwal (299895)

May 2017

Sensitivity analyses of cost-effectiveness results by age at time of treatment, cost of anti-HCV ...

Estimation of average diagnosis and treatment costs of hepatitis C

Hepatology From
Bed Bench
Sara Ashtari
Mohsen Vahedi
Mohamad Amin Pourhoseingholi
Asma Pourhoseingholi
Azadeh Safaee
Mohammad Reza Zali

August 2016

Aim: the objective of this study was to estimate the average cost of diagnosis and treatment of hepa...

Estimated per patient costs (£000s) related specifically to HCV related complications (excluding any HCV therapy costs) stratified by age, discounting, fibrosis stage and SVR.

Abstract

Extracted data

Estimated per patient costs (£000s) related specifically to HCV related complications (excluding any HCV therapy costs) stratified by age, discounting, fibrosis stage and SVR.

Abstract

Extracted data

Related items

Related items